153 related articles for article (PubMed ID: 3592366)
41. Estimation of absolute oral bioavailability of moxidectin in dogs using a semi-simultaneous method: influence of lipid co-administration.
Lallemand E; Lespine A; Alvinerie M; Bousquet-Melou A; Toutain PL
J Vet Pharmacol Ther; 2007 Oct; 30(5):375-80. PubMed ID: 17803727
[TBL] [Abstract][Full Text] [Related]
42. Pharmacokinetics of theophylline in beagle dogs and asthmatic patients after multiple oral doses of sustained-release theophylline tablet formulation.
Nosaka H; Takagi K; Hasegawa T; Ogura Y; Mizukami Y; Satake T
Int J Clin Pharmacol Ther Toxicol; 1986 Oct; 24(10):528-35. PubMed ID: 3781672
[TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetics of probenecid and the effect of oral probenecid administration on the pharmacokinetics of cefazolin in mares.
Donecker JM; Sams RA; Ashcraft SM
Am J Vet Res; 1986 Jan; 47(1):89-95. PubMed ID: 3946913
[TBL] [Abstract][Full Text] [Related]
44. Oral bioavailability of etoposide after administration of a single dose to tumor-bearing dogs.
Flory AB; Rassnick KM; Balkman CE; Kiselow MA; Autio K; Beaulieu BB; Lewis LD
Am J Vet Res; 2008 Oct; 69(10):1316-22. PubMed ID: 18828689
[TBL] [Abstract][Full Text] [Related]
45. Serum digoxin concentrations in dogs before, during, and after concomitant treatment with phenobarbital.
Pedersoli WM; Ganjam VK; Nachreiner RF
Am J Vet Res; 1980 Oct; 41(10):1639-42. PubMed ID: 7224289
[TBL] [Abstract][Full Text] [Related]
46. Effects of phenobarbital on digitoxin and digoxin elimination in the dog.
Breznock EM
Am J Vet Res; 1975 Apr; 36(4 Pt.1):371-3. PubMed ID: 1124874
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetics of total thyroxine in dogs after administration of an oral solution of levothyroxine sodium.
Le Traon G; Burgaud S; Horspool LJ
J Vet Pharmacol Ther; 2008 Apr; 31(2):95-101. PubMed ID: 18307500
[TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetics of cannabidiol in dogs.
Samara E; Bialer M; Mechoulam R
Drug Metab Dispos; 1988; 16(3):469-72. PubMed ID: 2900742
[TBL] [Abstract][Full Text] [Related]
49. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
[TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetics of primidone and its active metabolites in the dog.
Frey HH; Göbel W; Löscher W
Arch Int Pharmacodyn Ther; 1979 Nov; 242(1):14-30. PubMed ID: 543743
[TBL] [Abstract][Full Text] [Related]
51. Influence of induced cholestasis on pharmacokinetics of digoxin and digitoxin in dogs.
Miyazawa Y; Sato T; Kobayashi K; Akahori F; Suzuki T; Miyashita H
Am J Vet Res; 1990 Apr; 51(4):605-10. PubMed ID: 2327624
[TBL] [Abstract][Full Text] [Related]
52. Long-lasting enhancement of CYP activity after discontinuation of repeated administration of phenobarbital in dogs.
Fukunaga K; Saito M; Matsuo E; Muto M; Mishima K; Fujiwara M; Orito K
Res Vet Sci; 2009 Dec; 87(3):455-7. PubMed ID: 19406444
[TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetics of three formulations of diphenylhydantoin in the dog.
Overduin LM; van Gogh H; Mol JA; van Nes JJ
Res Vet Sci; 1989 Mar; 46(2):271-3. PubMed ID: 2704892
[TBL] [Abstract][Full Text] [Related]
54. Clinical tolerance and toxicity of intravenous baclofen: a pilot study in a canine model.
Krach LE; Kriel RL; Patterson EE; Scherkenbach LA; Coles LD; Cloyd JC
J Pediatr Rehabil Med; 2011; 4(2):89-98. PubMed ID: 21955965
[TBL] [Abstract][Full Text] [Related]
55. Ocular and serum disposition kinetics of cloxacillin after topical administration of benzathine cloxacillin and intravenous administration of sodium cloxacillin to calves.
Daigneault J; George LW; Baggot JD
Am J Vet Res; 1990 Mar; 51(3):381-5. PubMed ID: 2316914
[TBL] [Abstract][Full Text] [Related]
56. Pharmacokinetics of selenium administered parenterally at toxic doses in sheep.
Blodgett DJ; Bevill RF
Am J Vet Res; 1987 Mar; 48(3):530-4. PubMed ID: 3565910
[TBL] [Abstract][Full Text] [Related]
57. Treatment of clinically normal and cystinuric dogs with 2-mercaptopropionylglycine.
Hoppe A; Denneberg T; Kågedal B
Am J Vet Res; 1988 Jun; 49(6):923-8. PubMed ID: 3400930
[TBL] [Abstract][Full Text] [Related]
58. Comparison of histamine release induced by morphine and oxymorphone administration in dogs.
Robinson EP; Faggella AM; Henry DP; Russell WL
Am J Vet Res; 1988 Oct; 49(10):1699-701. PubMed ID: 2461130
[TBL] [Abstract][Full Text] [Related]
59. Pharmacokinetics of detomidine following intravenous or oral-transmucosal administration and sedative effects of the oral-transmucosal treatment in dogs.
Messenger KM; Hopfensperger M; Knych HK; Papich MG
Am J Vet Res; 2016 Apr; 77(4):413-20. PubMed ID: 27027842
[TBL] [Abstract][Full Text] [Related]
60. Phenobarbital pharmacokinetics and bioavailability in adults.
Nelson E; Powell JR; Conrad K; Likes K; Byers J; Baker S; Perrier D
J Clin Pharmacol; 1982; 22(2-3):141-8. PubMed ID: 7068937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
